Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $50.6250 (-3.77%) ($50.6250 - $50.6250) on Tue. Feb. 9, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.1% (three month average) | RSI | 53 | Latest Price | $50.6250(-3.77%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 1.3% a day on average for past five trading days. | Weekly Trend | IOVA advances 3.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(48%) XBI(44%) ARKG(43%) IWO(42%) ARKK(39%) | Factors Impacting IOVA price | IOVA will decline at least -1.55% in a week (0% probabilities). VIXM(-23%) UUP(-16%) VXX(-12%) TBT(-6%) UNG(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.55% (StdDev 3.1%) | Hourly BBV | -0.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $49.63(2%) | 10 Day Moving Average | $47.13(7.42%) | 20 Day Moving Average | $47.9(5.69%) | To recent high | -3.8% | To recent low | 40% | Market Cap | $7.413b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |